# SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.

> **NCT00412334** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 104 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Copegus
- **DRUG:** Copegus
- **DRUG:** peginterferon alfa-2a [Pegasys]
- **DRUG:** peginterferon alfa-2a [Pegasys]

## Key facts

- **NCT ID:** NCT00412334
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2016-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00412334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00412334, "SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00412334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*